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1. INTRODUCTION {#jmv25822-sec-0050}
===============

The 2019 novel coronavirus pneumonia (NCP) initially broke out in China, especially in Hubei province. The NCP is caused by a new coronavirus (SARS‐COV‐2) of the Sarbe virus subgenus, a member of orthocoronavirus subfamily.[^1^](#jmv25822-bib-0001){ref-type="ref"} SARS‐COV‐2 is a member of the coronavirus family along with SARS‐CoV and MERS‐CoV. With the deepening of research, more and more evidence show that its transmission channels are diversified, and its transmission speed and infectivity are stronger than SARS‐CoV and MERS‐CoV.[^2^](#jmv25822-bib-0002){ref-type="ref"}, [^3^](#jmv25822-bib-0003){ref-type="ref"}, [^4^](#jmv25822-bib-0004){ref-type="ref"} Since the outbreak of the epidemic, China has taken active prevention and control measures and achieved good results, but, recently, the epidemic situation abroad has begun to develop into an uncontrollable situation. As of 28 February 2020, the epidemic of NCP has affected six continents, and the epidemic situation in South Korea, Italy, Japan, and other countries is extremely serious. On 29 February, the "China‐WHO NCP (COVID‐19) Joint Inspection Report" stated that the NCP is almost susceptible to everyone on the same day. On 11 March, the WHO declared the SARS‐CoV‐2 outbreak as pandemic. Currently, published studies and case reports indicate that patients with NCP have very different clinical manifestations, laboratory tests, and imaging tests, making clinical diagnosis and treatment limited. Therefore, it is urgent to improve the understanding of the clinical characteristics of patients with NCP to further guide clinical and scientific research through evidence‐based medicine.

2. MATERIALS AND METHODS {#jmv25822-sec-0060}
========================

2.1. Search strategy and study selection {#jmv25822-sec-0070}
----------------------------------------

This study was approved by the Ethics Committee of the Tongji Medical College, Huazhong University of Science and Technology. The literature search was performed according to the PRISMA (preferred reporting items for systematic reviews and meta‐analyses) process. The search was conducted in five popular medical databases including three English databases (PubMed, Cochrane Library, and Embase) and two Chinese databases (National Knowledge Infrastructure \[CNKI\] and China Biology Medicine disc \[CBMdisc\]). The searches were concluded by 1 March 2020. The language limit is English and Chinese. The retrieval is a combination of subject words and free words, and the keywords are as follows: "2019 novel coronavirus pneumonia," "COVID‐19," "Coronavirus," "SARS‐CoV‐2," "Wuhan Coronavirus," "clinical features," "2019 novel coronavirus pneumonia," and "imaging features."

2.2. Inclusion/exclusion criteria {#jmv25822-sec-0080}
---------------------------------

Inclusive criteria are as follows: (a) research types: cross‐sectional studies and case series; (b) research subjects: patients with confirmed NCP, including patients with clinical diagnosis; and (c) data items: including clinical characteristics, biochemical indicators, and imaging signs. Exclusive criteria are as follows: (a) the type of study is case report, review, and so forth; (b) repeated research; and (c) lack of the above case data.

2.3. Data extraction and paper quality evaluation {#jmv25822-sec-0090}
-------------------------------------------------

The titles and abstracts of all retrieved references were independently reviewed by two investigators, and if there was any ambiguity in the search process, the decision was made by a third investigator. (a) The basic characteristics of the included literature are as follows: author, publication date, journal, research type, number of patients, quality score, and so forth. (b) The basic characteristics of the research subjects are as follows: age, sex, comorbidities, clinical manifestations, laboratory test results, imaging manifestations, and so on. The quality of all included literature was assessed using the Institute of Health Economics (IHE) scale.[^5^](#jmv25822-bib-0005){ref-type="ref"}

2.4. Statistical analysis {#jmv25822-sec-0100}
-------------------------

The statistical software Stata version 14.0 and Open Meta‐Analyst were used for meta‐analysis of single‐arm studies. We first unified all units of variables and, then, expressed classified variables as percentages and expressed continuous variables as mean ± standard deviation. The combined prevalence and 95% CI were calculated using a random‐effects model. We performed the Egger test to assess publication bias in all literature works, and *P* \< .05 was considered as publication bias.

3. RESULTS {#jmv25822-sec-0110}
==========

3.1. Literature inclusion and characteristics {#jmv25822-sec-0120}
---------------------------------------------

A total of 956 articles were retrieved. After deleting duplicates, 96 studies remained, of which 860 were excluded based on the title or abstract. Finally, 65 were eliminated after reading the full text, and a total of 31 articles[^6^](#jmv25822-bib-0006){ref-type="ref"}, [^7^](#jmv25822-bib-0007){ref-type="ref"}, [^8^](#jmv25822-bib-0008){ref-type="ref"}, [^9^](#jmv25822-bib-0009){ref-type="ref"}, [^10^](#jmv25822-bib-0010){ref-type="ref"}, [^11^](#jmv25822-bib-0011){ref-type="ref"}, [^12^](#jmv25822-bib-0012){ref-type="ref"}, [^13^](#jmv25822-bib-0013){ref-type="ref"}, [^14^](#jmv25822-bib-0014){ref-type="ref"}, [^15^](#jmv25822-bib-0015){ref-type="ref"}, [^16^](#jmv25822-bib-0016){ref-type="ref"}, [^17^](#jmv25822-bib-0017){ref-type="ref"}, [^18^](#jmv25822-bib-0018){ref-type="ref"}, [^19^](#jmv25822-bib-0019){ref-type="ref"}, [^20^](#jmv25822-bib-0020){ref-type="ref"}, [^21^](#jmv25822-bib-0021){ref-type="ref"}, [^22^](#jmv25822-bib-0022){ref-type="ref"}, [^23^](#jmv25822-bib-0023){ref-type="ref"}, [^24^](#jmv25822-bib-0024){ref-type="ref"}, [^25^](#jmv25822-bib-0025){ref-type="ref"}, [^26^](#jmv25822-bib-0026){ref-type="ref"}, [^27^](#jmv25822-bib-0027){ref-type="ref"}, [^28^](#jmv25822-bib-0028){ref-type="ref"}, [^29^](#jmv25822-bib-0029){ref-type="ref"}, [^30^](#jmv25822-bib-0030){ref-type="ref"}, [^31^](#jmv25822-bib-0031){ref-type="ref"}, [^32^](#jmv25822-bib-0032){ref-type="ref"}, [^33^](#jmv25822-bib-0033){ref-type="ref"}, [^34^](#jmv25822-bib-0034){ref-type="ref"}, [^35^](#jmv25822-bib-0035){ref-type="ref"}, [^36^](#jmv25822-bib-0036){ref-type="ref"} and 46 959 patients were included in this meta‐analysis (Figure [1](#jmv25822-fig-0001){ref-type="fig"}). The main characteristics of the included studies are shown in Table [1](#jmv25822-tbl-0001){ref-type="table"}. Publication bias was assessed with a funnel plot for the standard error by logit event, with no evidence of bias. Additionally, the Egger test (*P* = .091) suggested that there was no notable evidence of publication bias.

![Diagram of documents retrieval](JMV-9999-na-g001){#jmv25822-fig-0001}

###### 

The characteristics of the included literature

  References                                               Journal                              Year   Date (M/D)   Country   No. patient   Sex (male)   Average age   Research type         Quality
  -------------------------------------------------------- ------------------------------------ ------ ------------ --------- ------------- ------------ ------------- --------------------- ---------
  Huang et al[^6^](#jmv25822-bib-0006){ref-type="ref"}     *Lancet*                             2020   01/24        China     41            30           49            Retrospective study   8
  Chen et al[^7^](#jmv25822-bib-0007){ref-type="ref"}      *Lancet*                             2020   01/30        China     99            67           55.5          Retrospective study   8
  Yu et al[^35^](#jmv25822-bib-0035){ref-type="ref"}       *J Pract Med*                        2020   01/31        China     40            22           45.9          Retrospective study   5
  Michael et al[^8^](#jmv25822-bib-0008){ref-type="ref"}   *Radiology*                          2020   02/04        China     21            13           51            Retrospective study   5
  Wang et al[^9^](#jmv25822-bib-0009){ref-type="ref"}      *JAMA*                               2020   02/07        China     138           75           56            Retrospective study   8
  Liu et al[^10^](#jmv25822-bib-0010){ref-type="ref"}      *Chin J Pediatr*                     2020   02/07        China     137           61           57            Retrospective study   5
  Chang et al[^11^](#jmv25822-bib-0011){ref-type="ref"}    *JAMA*                               2020   02/07        China     13            10           34            Retrospective study   6
  Zheng et al[^12^](#jmv25822-bib-0012){ref-type="ref"}    *Shanghai Med J*                     2020   02/10        China     70                         ...           Retrospective study   4
  Liu et al[^13^](#jmv25822-bib-0013){ref-type="ref"}      *Sci China Life Sci*                 2020   02/12        China     12            8            ...           Retrospective study   6
  Gao et al[^14^](#jmv25822-bib-0014){ref-type="ref"}      *J Xi\'an Jiaotong Univ (Med Sci)*   2020   02/13        China     10            6            41.8          Retrospective study   5
  Gong et al[^15^](#jmv25822-bib-0015){ref-type="ref"}     *Radiol Prac*                        2020   02/13        China     33            13           51            Retrospective study   5
  Pan et al[^16^](#jmv25822-bib-0016){ref-type="ref"}      *Eur Radiol*                         2020   02/13        China     63            33           ...           Retrospective study   6
  Liu et al[^17^](#jmv25822-bib-0017){ref-type="ref"}      *Preprint Lancet*                    2020   02/13        China     24            8            43            Retrospective study   6
  Pan et al[^18^](#jmv25822-bib-0018){ref-type="ref"}      *Radiology*                          2020   02/13        China     21            6            40.9          Retrospective study   5
  Zhang et al[^19^](#jmv25822-bib-0019){ref-type="ref"}    *Chin J Tuberc Respir Dis*           2020   02/15        China     9             5            36            Case series           5
  Feng et al[^20^](#jmv25822-bib-0020){ref-type="ref"}     *Chin J Pediatr*                     2020   02/17        China     15            5            ...           Case series           5
  Wang et al[^21^](#jmv25822-bib-0021){ref-type="ref"}     *Chin J Pediatr*                     2020   02/17        China     34            14           8             Retrospective study   5
  Zhang et al[^22^](#jmv25822-bib-0022){ref-type="ref"}    *J. Chin Epi*                        2020   02/17        China     44 672        22 981       ...           Retrospective study   6
  Liu et al[^23^](#jmv25822-bib-0023){ref-type="ref"}      *Radiol Prac*                        2020   02/18        China     41            32           48.45         Retrospective study   5
  Zhuang et al[^24^](#jmv25822-bib-0024){ref-type="ref"}   *Chin J Nosocomiology*               2020   02/19        China     26            18           ...           Retrospective study   6
  Wang et al[^25^](#jmv25822-bib-0025){ref-type="ref"}     *J Clin Med*                         2020   02/19        China     30            16           ...           Retrospective study   5
  Chen et al[^26^](#jmv25822-bib-0026){ref-type="ref"}     *Herald Med*                         2020   02/19        China     54            27           58.5          Retrospective study   5
  Zhong et al[^27^](#jmv25822-bib-0027){ref-type="ref"}    *Med J Wuhan Univ*                   2020   02/19        China     30            18           50.17         Retrospective study   5
  Fu et al[^28^](#jmv25822-bib-0028){ref-type="ref"}       *Med J Wenzhou Univ*                 2020   02/20        China     35            21           47            Retrospective study   5
  Yang et al[^29^](#jmv25822-bib-0029){ref-type="ref"}     *Lancet Respir Med*                  2020   02/21        China     52            35           59.7          Retrospective study   7
  Ji et al[^30^](#jmv25822-bib-0030){ref-type="ref"}       *Chin J Med Imaging Technol*         2020   02/24        China     45            27           45.4          Retrospective study   6
  Chen et al[^36^](#jmv25822-bib-0036){ref-type="ref"}     *Chin J Tuberc Respir Dis*           2020   02/25        China     29            21           56            Retrospective study   5
  Chen et al[^31^](#jmv25822-bib-0031){ref-type="ref"}     *J Clin Med*                         2020   02/26        China     12            8            63            Retrospective study   4
  Zeng et al[^32^](#jmv25822-bib-0032){ref-type="ref"}     *J Emerg Tradit Chin Med*            2020   02/27        China     18            10           45.94         Retrospective study   5
  Cao et al[^33^](#jmv25822-bib-0033){ref-type="ref"}      *Med J Wuhan Univ*                   2020   02/28        China     36            20           72.45         Retrospective study   5
  Guan et al[^34^](#jmv25822-bib-0034){ref-type="ref"}     *NEJM*                               2020   02/29        China     1099          640          47            Retrospective study   8
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3.2. Meta‐analysis results {#jmv25822-sec-0130}
--------------------------

### 3.2.1. Demographical characteristics and comorbidities {#jmv25822-sec-0140}

The mean age of the patients with SARS‐COV‐2 infection was 46.62 (95% CI, 31.710‐61.531) and 55.6% (95% CI, 0.530‐0.602) were male. About 35.6% (0.267‐0.444) of patients had comorbidities, including 18.3% (0.130‐0.236) with hypertension, 11.2% (0.078‐0.145) with cardiovascular disease, 10.3% (0.069‐0.136) with diabetes, 3.9% (0.011‐0.067) with chronic obstructive pulmonary disease, 3.0% (0.021‐0.039) with chronic hepatonephropathy, and 1.1% (0.003‐0.020) with tumor (Table [2](#jmv25822-tbl-0002){ref-type="table"} and Figures [2](#jmv25822-fig-0002){ref-type="fig"} and [3](#jmv25822-fig-0003){ref-type="fig"}).

###### 

Meta‐analysis results of the incidence of demographical and comorbidities

  Variable                    *N* [^a^](#jmv25822-tbl2-note-0002){ref-type="fn"}   Estimate   95% CI            N[^b^](#jmv25822-tbl2-note-0003){ref-type="fn"}   Standard error   *P*      *T* ^2^   *Q*        *P* [^c^](#jmv25822-tbl2-note-0004){ref-type="fn"}   *I* ^2^
  --------------------------- ---------------------------------------------------- ---------- ----------------- ------------------------------------------------- ---------------- -------- --------- ---------- ---------------------------------------------------- ---------
  Sex, male                   30                                                   0.556      0.530 to 0.602    24 250                                            0.018            \<.001   0.004     104.391    \<.001                                               72.22
  Age, mean                   14                                                   46.62      31.71 to 61.531   334                                               7.608            \<.001   801.948   2756.956   \<.001                                               99.528
  ICU                         9                                                    0.293      0.190 to 0.395    2371                                              0.052            \<.001   0.022     487.408    \<.001                                               98.359
  Comorbidities               10                                                   0.356      0.267 to 0.444    464                                               0.045            \<.001   0.015     75.378     \<.001                                               88.06
  Tumor                       8                                                    0.011      0.003 to 0.020    135                                               0.004            .009     0.000     22.143     .002                                                 68.387
  Diabetes                    13                                                   0.103      0.069 to 0.136    1261                                              0.017            \<.001   0.002     97.488     \<.001                                               87.691
  Hypertension                12                                                   0.183      0.130 to 0.236    2964                                              0.027            \<.001   0.006     160.717    \<.001                                               93.156
  Cardiovascular disease      11                                                   0.112      0.078 to 0.145    1023                                              0.017            \<.001   0.002     136.694    \<.001                                               92.684
  Phthisis                    3                                                    0.021      −0.005 to 0.047   515                                               0.013            .120     0.000     2.655      .265                                                 24.672
  COPD                        8                                                    0.039      0.011 to 0.067    46                                                0.014            .006     0.001     53.971     \<.001                                               87.03
  Chronic hepatonephropathy   7                                                    0.030      0.021 to 0.039    46                                                0.005            \<.001   0.000     5.144      .525                                                 0

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.

Number of studies.

Number of patients.

Heterogeneity *P* value.
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![The forest plots of age and sex. A, age and (B) sex](JMV-9999-na-g002){#jmv25822-fig-0002}

![The forest plots of the incidence of comorbidities and intensive care unit (ICU). A, Comorbidities; (B) tumor; (C) diabetes; (D) hypertension; (E) cardiovascular disease; (F) phthisis; (G) chronic obstructive pulmonary disease; (H) chronic hepatonephropathy; (I) ICU](JMV-9999-na-g003){#jmv25822-fig-0003}

### 3.2.2. Clinical features {#jmv25822-sec-0150}

The incidence of fever was 87.3% (0.838‐0.909), that of cough was 58.1% (0.502‐0.660), that of sore throat was 12% (0.062‐0.177), that of expectoration was 29.4% (0.171‐0.417), that of chest distress was 31.2% (−0.024 to 0.648), that of muscle soreness or fatigue was 35.5% (0.253‐0.456), that of headache was 9.4% (0.063‐0.126), that of diarrhea was 6.8% (0.044‐0.092), and that of dyspnea was 38.3% (0.246‐0.520) (Table [3](#jmv25822-tbl-0003){ref-type="table"} and Figure [4](#jmv25822-fig-0004){ref-type="fig"}).

###### 

Meta‐analysis results of the incidence of clinical manifestations

  Variable                     *N* [^a^](#jmv25822-tbl3-note-0002){ref-type="fn"}   Estimate   95% CI            N[^b^](#jmv25822-tbl3-note-0003){ref-type="fn"}   Standard error   *P*      *T* ^2^   *Q*       *P* [^c^](#jmv25822-tbl3-note-0004){ref-type="fn"}   *I* ^2^
  ---------------------------- ---------------------------------------------------- ---------- ----------------- ------------------------------------------------- ---------------- -------- --------- --------- ---------------------------------------------------- ---------
  Fever                        27                                                   0.873      0.838 to 0.909    1842                                              0.018            \<.001   0.006     177.086   \<.001                                               85.318
  Cough                        27                                                   0.581      0.502 to 0.660    1354                                              0.040            \<.001   0.037     332.025   \<.001                                               92.169
  Sore throat                  9                                                    0.120      0.062 to 0.177    200                                               0.029            \<.001   0.005     58.432    \<.001                                               86.309
  Expectoration                10                                                   0.294      0.171 to 0.417    466                                               0.063            \<.001   0.035     266.04    \<.001                                               96.617
  Chest distress               5                                                    0.312      −0.024 to 0.648   38                                                0.172            .069     0.144     204.480   \<.001                                               98.044
  Muscle soreness or fatigue   18                                                   0.355      0.253 to 0.456    781                                               0.052            \<.001   0.038     220.594   \<.001                                               92.747
  Headache                     14                                                   0.094      0.063 to 0.126    214                                               0.016            \<.001   0.002     37.648    \<.001                                               65.47
  Diarrhea                     15                                                   0.068      0.044 to 0.092    103                                               0.012            \<.001   0.001     32.263    .004                                                 56.607
  Dyspnea                      11                                                   0.383      0.246 to 0.520    409                                               0.070            \<.001   0.051     351.966   \<.001                                               97.159

Abbreviation: CI, confidence interval.

Number of studies.

Number of patients.

Heterogeneity *P* value.
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![The forest plots of the incidence of clinical features. A, Fever; (B) cough; (C) sore throat; (D) expectoration; (E) chest distress; (F) muscle soreness or fatigue; (G) headache; (H) diarrhea; (I) dyspnea](JMV-9999-na-g004){#jmv25822-fig-0004}

### 3.2.3. Laboratory tests {#jmv25822-sec-0160}

The laboratory findings showed leukocytosis in 11.0% (0.070‐0.150), leukopenia in 36.9% (0.146‐0.593), lymphocytopenia in 57.4% (0.410‐0.737), high C‐reactive protein (CRP) in 61.3% (0.451‐0.774), high lactate dehydrogenase (LDH) in 57.0% (0.360‐0.780), and high erythrocyte sedimentation rate (ESR) in 42.2% (0.076‐0.767) (Table [4](#jmv25822-tbl-0004){ref-type="table"} and Figure [5](#jmv25822-fig-0005){ref-type="fig"}).

###### 

Meta‐analysis results of the incidence of laboratory tests

  Variable          *N* [^a^](#jmv25822-tbl4-note-0002){ref-type="fn"}   Estimate   95% CI        N[^b^](#jmv25822-tbl4-note-0003){ref-type="fn"}   Standard error   *P*      *T* ^2^   *Q*        *P* [^c^](#jmv25822-tbl4-note-0004){ref-type="fn"}   *I* ^2^   
  ----------------- ---------------------------------------------------- ---------- ------------- ------------------------------------------------- ---------------- -------- --------- ---------- ---------------------------------------------------- --------- --------
  Leukocytosis                                                           13         0.110         0.070‐0.150                                       141              0.020    \<.001    0.003      115.035                                              \<.001    89.568
  Leukopenia        16                                                   0.369      0.146‐0.593   541                                               0.114            .001     0.204     5837.766   \<.001                                               99.743    
  Lymphocytopenia   16                                                   0.574      0.410‐0.737   1157                                              0.083            \<.001   0.105     1113.409   \<.001                                               98.653    
  High CRP          15                                                   0.613      0.451‐0.774   910                                               0.082            \<.001   0.089     564.423    \<.001                                               97.697    
  High LDH          7                                                    0.570      0.360‐0.780   477                                               0.107            \<.001   0.076     236.597    \<.001                                               97.464    
  High ESR          5                                                    0.422      0.076‐0.767   132                                               0.176            .017     0.151     188.792    \<.001                                               97.881    

Abbreviations: CI, confidence interval; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase.

Number of studies.

Number of patients.

Heterogeneity *P* value.
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![The forest plots of the incidence of laboratory test features. A, Leukocytosis; (B) leukopenia; (C) lymphocytopenia; (D) high C‐reactive protein; (E) high lactate dehydrogenase; (F) high erythrocyte sedimentation rate](JMV-9999-na-g005){#jmv25822-fig-0005}

### 3.2.4. Imaging features {#jmv25822-sec-0170}

At the chest computed tomography (CT), the pneumonia compromise was predominantly bilateral in 75.5% (0.639‐0.871) and unilateral 20.4% (0.106‐0.302). The most common patterns on chest CT were ground‐glass (69.9%, 0.602‐0.796), followed by irregular or halo sign (54.4%, 0.255‐0.833), air bronchogram (51.3%, 0.326‐0.701), bronchovascular bundle thickening (39.5%, 0.082‐0.708), grid‐form shadow (24.4%, 0.116‐0.371), and hydrothorax (18.5%, 0.001‐0.370) (Table [5](#jmv25822-tbl-0005){ref-type="table"} and Figure [6](#jmv25822-fig-0006){ref-type="fig"}).

###### 

Meta‐analysis results of the incidence of chest imaging

  Variable                             *N* [^a^](#jmv25822-tbl5-note-0002){ref-type="fn"}   Estimate   95% CI        N[^b^](#jmv25822-tbl5-note-0003){ref-type="fn"}   Standard error   *P*      *T* ^2^   *Q*        *P* [^c^](#jmv25822-tbl5-note-0004){ref-type="fn"}   *I* ^2^
  ------------------------------------ ---------------------------------------------------- ---------- ------------- ------------------------------------------------- ---------------- -------- --------- ---------- ---------------------------------------------------- ---------
  Unilateral                           19                                                   0.204      0.106‐0.302   522                                               0.050            \<.001   0.043     751.641    \<.001                                               97.605
  Bilateral                            21                                                   0.755      0.639‐0.871   1196                                              0.059            \<.001   0.068     1582.357   \<.001                                               98.736
  Lung consolidation                   9                                                    0.369      0.215‐0.523   122                                               0.079            \<.001   0.050     96.579     \<.001                                               91.717
  Ground‐glass                         21                                                   0.699      0.602‐0.796   1413                                              0.049            \<.001   0.047     1482.862   \<.001                                               98.651
  Air bronchogram                      6                                                    0.513      0.326‐0.701   119                                               0.096            \<.001   0.048     49.183     \<.001                                               89.834
  Grid‐form shadow                     6                                                    0.244      0.116‐0.371   64                                                0.065            \<.001   0.022     39.574     \<.001                                               87.365
  Bronchovascular bundles thickening   4                                                    0.395      0.082‐0.708   41                                                0.160            .013     0.097     68.065     \<.001                                               95.592
  Hydrothorax                          7                                                    0.185      0.001‐0.370   23                                                0.094            .049     0.059     281.788    \<.001                                               97.871
  Irregular or halo sign               5                                                    0.544      0.255‐0.833   107                                               0.148            \<.001   0.104     105.731    \<.001                                               96.217

Abbreviation: CI, confidence interval.

Number of studies.

Number of patients.

Heterogeneity *P* value.
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![The forest plots of the incidence of imaging features. A, Unilateral; (B) bilateral; (C) lung consolidation; (D) ground‐glass; (E) air bronchogram; (F) grid‐form shadow; (G) bronchovascular bundles thickening; (H) hydrothorax; (I) irregular or halo sign](JMV-9999-na-g006){#jmv25822-fig-0006}

### 3.2.5. Complications and outcomes {#jmv25822-sec-0180}

Among the infected patients, severe cases who required intensive care unit (ICU) were 29.3% (0.190‐0.395), and the incidence of acute respiratory distress syndrome (ARDS) was 28.8% (0.147‐0.429), that of acute cardiac injury was 14.1% (0.079‐0.204), that of acute renal injury was 7.1% (0.031‐0.110), that of shock was 4.7% (0.009‐0.086), that of multiple organ dysfunction syndrome (MODS) was 8.5% (−0.008 to 0.179), and the case fatality rate was 6.8% (0.044‐0.093) (Table [6](#jmv25822-tbl-0006){ref-type="table"} and Figure [7](#jmv25822-fig-0007){ref-type="fig"}).

###### 

Meta‐analysis results of the incidence of complications

  Variable    *N* [^a^](#jmv25822-tbl6-note-0002){ref-type="fn"}   Estimate   95% CI            N[^b^](#jmv25822-tbl6-note-0003){ref-type="fn"}   Standard error   *P*      *T* ^2^   *Q*       *P* [^c^](#jmv25822-tbl6-note-0004){ref-type="fn"}   *I* ^2^
  ----------- ---------------------------------------------------- ---------- ----------------- ------------------------------------------------- ---------------- -------- --------- --------- ---------------------------------------------------- ---------
  ARDS        8                                                    0.288      0.147 to 0.429    160                                               0.072            \<.001   0.037     195.606   \<.001                                               96.421
  ACI         7                                                    0.141      0.079 to 0.204    151                                               0.032            \<.001   0.005     49.732    \<.001                                               87.935
  ARI         8                                                    0.071      0.031 to 0.110    58                                                0.02             \<.001   0.002     36.801    \<.001                                               80.979
  Shock       5                                                    0.047      0.009 to 0.086    31                                                0.020            .016     0.001     15.319    .004                                                 73.889
  MODS        4                                                    0.085      −0.008 to 0.179   9                                                 0.048            .074     0.004     5.050     .080                                                 60.392
  Mortality   8                                                    0.068      0.044 to 0.093    1111                                              0.012            \<.001   0.001     110.944   \<.001                                               93.69

Abbreviations: ACI, acute cardiac injury; ARDS, acute respiratory distress syndrome; ARI, acute renal injury; CI, confidence interval; MODS, multiple organ dysfunction syndrome.

Number of studies.

Number of patients.

Heterogeneity *P* value.
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![The forest plots of the incidence of complication. A, acute respiratory distress syndrome; (B) acute cardiac injury; (C) acute renal injury; (D) shock; (E) multiple organ dysfunction syndrome; (F) mortality](JMV-9999-na-g007){#jmv25822-fig-0007}

4. DISCUSSION {#jmv25822-sec-0190}
=============

The results of this study showed that fever (87.3%) and cough (58.1%) were the main clinical manifestations in the patients with NCP in China. This was followed by dyspnea (38.3%), myalgia or weakness (35.5%), and chest tightness (31.2%), and some patients also presented other clinical symptoms such as chills, cough, conjunctival discomfort, headache, shortness of breath, and joint pain. A few patients had nausea, vomiting, diarrhea, and other abdominal discomfort symptoms, whereas very few patients showed hemoptysis symptoms. Most patients with NCP required hospitalization, of which 29.3% required intensive care. The main complications are respiratory failure, ARDS (28.8%) and multiple organ failure (8.5%), and heart failure, shock, renal injury, sepsis, striated muscle lysis, and diffuse intravascular coagulation are rare. According to the severity, the patients with NCP can be divided into mild, normal type (80%), medium type, and severe type (13.8%). The clinical manifestations of patients with different severity vary greatly. According to statistics, the fatality rate in China is about 3.8%,[^37^](#jmv25822-bib-0037){ref-type="ref"} lower than that of SARS (9.6%) and MERS (35%). The main causes of death are massive alveolar damage and progressive respiratory failure. Generally, viral pneumonia mainly involves pulmonary interstitium, producing pulmonary interstitial fibrosis. The autopsy report of the first NCP patient in China found that coronavirus disease 2019 (COVID‐19) mainly caused the inflammatory response characterized by deep airway and alveolar damage, accompanied by a large amount of viscous secretions in the airway. The pulmonary transparent membrane became less obvious, and the degree of fibrosis was not as severe as SARS.[^38^](#jmv25822-bib-0038){ref-type="ref"} However, the degree of effect of COVID‐19 on pulmonary fibrosis still needs to be paid close attention, which is also an important factor influencing pulmonary function in the prognosis of patients with NCP.

In this meta‐analysis, white blood cells were normal or decreased in most patients, lymphocytes were mostly decreased, and CRP, LDH, ESR level was elevated in some patients. A few patients had elevated creatine kinase procalcitonin bilirubin, whereas some had decreased albumin and elevated ALT, AST. The pathological results of patients with SARS‐COV‐2 suggested that the excessive activation of T lymphocytes, which is characterized by increased Th17 cells and high toxicity of CD8^+^ T cells, has caused severe immune damage to a certain extent.[^4^](#jmv25822-bib-0004){ref-type="ref"} This may be the main reason for the loss of lymphocytes in patients. Sequence comparison analysis showed that the S spike protein of SARS‐COV‐2 contains a SARS‐CoV‐like receptor binding domain, which indicates that ACE2 may be the main receptor of SARS‐COV‐2.[^3^](#jmv25822-bib-0003){ref-type="ref"} ACE2 was highly expressed in gastric and testicular epithelial cells, and also enriched in colon, heart, kidney, and so on. Over‐expressed ACE2 may be related to the elevated liver enzyme.[^39^](#jmv25822-bib-0039){ref-type="ref"} The similarity of SARS‐COV‐2 and SARS‐CoV gene sequences suggests that the mechanism of action may also be similar. SARS‐COV‐2 enters host cells through dense S protein,[^40^](#jmv25822-bib-0040){ref-type="ref"}, [^41^](#jmv25822-bib-0041){ref-type="ref"} acts on bronchial epithelial cells through ACE2 receptor, and then infects other cells, causing a series of immune responses or inflammatory cytokine storm in severe cases. In addition, the sequence alignment showed that the SARS‐COV‐2 and SARS‐CoV S2 subunits are highly conserved, and the overall identity in the HR1 and HR2 domains is 92.6% and 100%, respectively. This suggested that novel coronary pneumonia drugs research may base on this site.[^42^](#jmv25822-bib-0042){ref-type="ref"}

In imaging results, this meta‐analysis showed that 75.7% of the patients had lesions involving both lungs, and 69.9% showed ground‐glass shadows on imaging, mostly interstitial pulmonary lesions. Chest CT showed consolidation shadow nodular or patchy shadow in some patients, whereas there also existed other characteristics in few patients, such as chest‐shaped shadows, thick cord‐like shadows, pleural reactions, thickened blood vessels, pleural effusion, and bronchial inflation, subpleural line, halo sign, antihalo sign, mosaic sign, and so on. The course of the critically ill patient progressed rapidly, and chest CT could cause "white lung" changes within a few days. Because the sensitivity of nucleic acid test is closely related to the detection sample and testing the sample of lower respiratory tract is more sensitive,[^43^](#jmv25822-bib-0043){ref-type="ref"} nucleic acid test shows partial false negative result. Chest CT examination, as an important examination method for NCP, is highly sensitive to SARS‐COV‐2 (even up to 97% in epidemic areas) and is an important supplement to nucleic acid detection.[^44^](#jmv25822-bib-0044){ref-type="ref"} In patients with negative nucleic acid test reports, chest CT results are still of high auxiliary diagnostic value. In addition, imaging manifestations of patients also show dynamic evolution in the course of disease progression.

Current research showed that COVID‐19, which source may be Chinese chrysanthemum head bats and pangolin may be a potential intermediate host, can cause a zoonotic disease.[^3^](#jmv25822-bib-0003){ref-type="ref"} Since late February 2020, the number of confirmed cases of NCP abroad has increased rapidly, which may indicate a pandemic. The "three early" principle (early detection, early diagnosis, and early treatment) followed by disease prevention and treatment is particularly important in the prevention and treatment of SARS‐COV‐2. In addition, the clinical manifestations of patients with neocoronary pneumonia are diverse and the atypical symptoms also account for part of the proportion. Therefore, we systematically analyzed the clinical manifestations and auxiliary examination results of patients with COVID‐19, so as to reflect the disease characteristics more comprehensively, increase the discrimination of the disease, and strive for early diagnosis, early isolation, and early treatment.

The number of newly diagnosed cases of NCP has been rising worldwide recently, especially in South Korea, Italy, Iran, and Japan. To control the further spread of the epidemic, it is still necessary to strictly follow the management measures for the prevention and treatment of infectious diseases and follow the WHO declaration on public health emergencies of international concern. Certainly, prevention of imported cases is also extremely important.[^45^](#jmv25822-bib-0045){ref-type="ref"} Particularly, in some densely populated markets, stations, large ports, and other places, protective deployment measures should be strengthened to ensure that protective equipment, drugs, medical supplies, and so on are sufficient.[^46^](#jmv25822-bib-0046){ref-type="ref"} National public health capabilities and infrastructure remain at the core of global health security, as they are the first line of defense for infectious disease emergencies.[^47^](#jmv25822-bib-0047){ref-type="ref"} The International Health Organization, all countries, and all humanity need to pay great attention to SARS‐COV‐2.

This meta‐analysis, with large enough sample size, relatively high literature quality, and more comprehensive analysis, included a total of 31 literature studies, including 46 959 patients with NCP. The conclusions are very credible to some extent. This article still has the following limitations, for example, (a) the samples are domestic cases, without foreign cases; (b) different data sources may lead to some bias in the results; and (c) there exists some publication bias. Therefore, the conclusions of this article need to be further verified.

5. CONCLUSION {#jmv25822-sec-0200}
=============

COVID‐19 is a new clinical infectious disease, which mainly causes bilateral pneumonia and lung function deteriorates rapidly. Nearly a third of patients need to be admitted to the ICU, and patients are likely to present respiratory failure or even death.
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